comparemela.com

Latest Breaking News On - Arie belldegrun - Page 14 : comparemela.com

Synbio Powerhouse Ginkgo Bioworks Goes Public in $17 5B SPAC Deal

Synbio Powerhouse Ginkgo Bioworks Goes Public in $17.5B SPAC Deal May 11, 2021 Synthetic biology powerhouse Ginkgo Bioworks will become a public company through a $17.5 billion merger with a special purpose acquisition company (SPAC) that is expected to provide up to $2.5 billion of gross cash proceeds. [Ginkgo Bioworks] Share Synthetic biology powerhouse Ginkgo Bioworks said today it will become a public company through a $17.5 billion merger with a special purpose acquisition company (SPAC) that is expected to provide up to $2.5 billion of gross cash proceeds. The SPAC business combination with Soaring Eagle Acquisition Corp. implies a pre-money equity valuation of $15 billion for Ginkgo, the company said. Soaring Eagle will change its name to Ginkgo Bioworks Holdings, change its jurisdiction of formation to Delaware and change its ticker symbol from SRNG to a new symbol.

Ginkgo Bioworks To Go Public In $17 5 Billion Deal With Hollywood Exec Harry Sloan s SPAC

09:49am EDT| Ginkgo Bioworks To Go Public In $17.5 Billion Deal With Former Hollywood Exec Harry Sloan’s SPAC Share to Facebook Michael Prince for Forbes Synthetic biology pioneer Ginkgo Bioworks agreed to go public today in a $17.5 billion SPAC deal. The Boston-based company will merge with Soaring Eagle Acquisition Corp., a blank-check firm founded by former Hollywood exec Harry Sloan in a giant deal for SPAC companies on Nasdaq. “It’s a really fun time now, actually,” says Ginkgo cofounder and CEO Jason Kelly. “Covid-19 has had a weird effect on biology awareness. Proteins are on the cover of The New York Times. I was on ‘60 Minutes.’ My parents know what PCR is now. I think it’s a really good moment to bring more of this into people’s lives.”

Synbio firm Ginkgo Bioworks engineers a SPAC deal to go public at a $15B valuation

Ginkgo plans a $17 5 billion merger with SPAC that took DraftKings public

Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public Jonathan Saltzman © Scott Eisen Jason Kelly, cofounder and chief executive of Ginkgo Bioworks. Ginkgo Bioworks, one of the hottest biotech startups in Massachusetts, said Tuesday that it plans to go public through a $17.5 billion merger with a so-called blank check company backed by Harry Sloan and Jeff Sagansky, the veteran media industry executives who helped take the Boston sports-betting company DraftKings public last year. Popular Searches The deal values Ginkgo at $15 billion, making the merger one of the biggest of its kind. Ginkgo programs cells to produce new proteins, scents, antibiotics, cannabinoids, and other products for a growing array of industries. Launched in 2008 by five scientists from the Massachusetts Institute of Technology, it now employs about 500 people, most of them in Boston’s Seaport.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.